Cargando…

IgGs from patients with amyotrophic lateral sclerosis and diabetes target Ca(V)α(2)δ1 subunits impairing islet cell function and survival

Patients with amyotrophic lateral sclerosis (ALS) often show hallmarks of type 2 diabetes mellitus (T2DM). However, the causal link between ALS and T2DM has remained a mystery. We now demonstrate that 60% of ALS patients with T2DM (ALS-T2DM) have sera that exaggerated K(+)-induced increases in cytos...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yue, Park, Kyoung Sun, Kim, Seung Hyun, Yu, Jia, Zhao, Kaixuan, Yu, Lina, Oh, Ki Wook, Lee, Kayoung, Kim, Jaeyoon, Chaggar, Kanchan, Li, Yuxin, Dolphin, Annette C., Catterall, William A., Ryu, Sung Ho, Yang, Shao-Nian, Berggren, Per-Olof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936400/
https://www.ncbi.nlm.nih.gov/pubmed/31826954
http://dx.doi.org/10.1073/pnas.1911956116
Descripción
Sumario:Patients with amyotrophic lateral sclerosis (ALS) often show hallmarks of type 2 diabetes mellitus (T2DM). However, the causal link between ALS and T2DM has remained a mystery. We now demonstrate that 60% of ALS patients with T2DM (ALS-T2DM) have sera that exaggerated K(+)-induced increases in cytosolic free Ca(2+) concentration ([Ca(2+)](i)) in mouse islet cells. The effect was attributed to the presence of pathogenic immunoglobulin Gs (IgGs) in ALS-T2DM sera. The pathogenic IgGs immunocaptured the voltage-dependent Ca(2+) (Ca(V)) channel subunit Ca(V)α(2)δ1 in the plasma membrane enhancing Ca(V)1 channel-mediated Ca(2+) influx and [Ca(2+)](i), resulting in impaired mitochondrial function. Consequently, impairments in [Ca(2+)](i) dynamics, insulin secretion, and cell viability occurred. These data reveal that patients with ALS-T2DM carry cytotoxic ALS-T2DM-IgG autoantibodies that serve as a causal link between ALS and T2DM by immunoattacking Ca(V)α(2)δ1 subunits. Our findings may lay the foundation for a pharmacological treatment strategy for patients suffering from a combination of these diseases.